🇯🇵·17h agoIndustry
Update on the Phase 3 STAR-121 Study of Anti-TIGIT Antibody Domvanalimab and Anti-PD-1 Antibody Zimberelimab in Non-Small Cell Lung Cancer
Publisher
O
Otsuka Holdings RSS
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on taiho.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Holdings RSS
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News·6h ago
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Roche Newsroom·12h ago
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Hyman, Phelps & McNamara (FDA Law)·14h ago
FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (Post 1 of 2)
Cibeles (Uruguay)·16h ago